Enhanced benefit from house dust mite immunotherapy in subjects with low serum levels of LILRA5 or CCL25.

The article discusses a study that aimed to identify predictive markers of allergen immunotherapy (AIT) efficacy in house dust mite allergic subjects. The study found that low serum levels of Leukocyte Immunoglobulin-Like Receptor A5 (LILRA5) and C-C motif chemokine ligand 25 (CCL25) were associated with enhanced benefits from AIT. These markers are known to play roles in inflammation-related diseases, including allergy and asthma. The findings suggest that patients with lower levels of LILRA5 and CCL25 may have a less inflammatory status, making them more responsive to AIT. Further research is needed to validate these markers and explore personalized treatment options for allergic patients. [Extracted from the article]